Fibrosis in chronic viral hepatitis
- PMID: 21497740
- DOI: 10.1016/j.bpg.2011.02.012
Fibrosis in chronic viral hepatitis
Abstract
In the last years, several studies have been performed with the aim to evaluate the real impact of antiviral treatments on fibrosis progression in patients with chronic viral hepatitis. The main goal of therapy in patients with chronic hepatitis B is viral suppression. This outcome leads to an important improvement in both hepatic inflammation and fibrosis and reduces the HCC occurrence. An histological improvement has been largely demonstrated in patient treated with oral nucleoside and nucleotide analogs achieving the rate of 72% with entecavir and tenofovir. Similarly, in patients with chronic hepatitis C, sustained virologic response to interferon therapy is associated with regression of fibrosis and lower liver decompensation and HCC occurrence. In the next future further studies will assess the real impact of the new directly anti-viral agents on liver necroinflammation and fibrosis in chronic hepatitis C.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs.Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):187-98. doi: 10.1586/egh.12.4. Expert Rev Gastroenterol Hepatol. 2012. PMID: 22375524 Review.
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.Antivir Ther. 2010;15(4):617-31. doi: 10.3851/IMP1570. Antivir Ther. 2010. PMID: 20587855
-
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.Clin Infect Dis. 2008 Mar 1;46(5):768-74. doi: 10.1086/527565. Clin Infect Dis. 2008. PMID: 18248298
-
Reversibility of cirrhosis in HIV/HBV coinfection.Antivir Ther. 2007;12(2):279-83. Antivir Ther. 2007. PMID: 17503671
-
Review article: predicting response in hepatitis C virus therapy.Aliment Pharmacol Ther. 2006 Apr 15;23(8):1043-54. doi: 10.1111/j.1365-2036.2006.02863.x. Aliment Pharmacol Ther. 2006. PMID: 16611264 Review.
Cited by
-
Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis.J Tradit Chin Med. 2023 Jun;43(3):559-567. doi: 10.19852/j.cnki.jtcm.20230208.002. J Tradit Chin Med. 2023. PMID: 37147758 Free PMC article.
-
Quantitative Assessment of Liver Impairment in Chronic Viral Hepatitis with [99mTc]Tc-Mebrofenin: A Noninvasive Attempt to Stage Viral Hepatitis-Associated Liver Fibrosis.Medicina (Kaunas). 2022 Sep 23;58(10):1333. doi: 10.3390/medicina58101333. Medicina (Kaunas). 2022. PMID: 36295494 Free PMC article.
-
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.Drug Des Devel Ther. 2022 Sep 23;16:3263-3274. doi: 10.2147/DDDT.S376821. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36177347 Free PMC article. Clinical Trial.
-
Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance.Dig Dis Sci. 2022 Jan;67(1):321-328. doi: 10.1007/s10620-021-06845-2. Epub 2021 Jan 30. Dig Dis Sci. 2022. PMID: 33517556 Free PMC article.
-
Clinical Efficacy and Safety of Eight Traditional Chinese Medicine Combined with Entecavir in the Treatment of Chronic Hepatitis B Liver Fibrosis in Adults: A Network Meta-Analysis.Evid Based Complement Alternat Med. 2020 Sep 30;2020:7603410. doi: 10.1155/2020/7603410. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 33062022 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
